 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...1011121314151617181920...4748» |
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5647;
This preliminary analysis indicated that chemotherapy combined with anlotinib, toripalimab, and stereotactic radiotherapy had promising efficacy and favorable tolerance as treatment of oligo-metastatic NPC. Clinical trial information: ChiECRCT20210147.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5564;
P2
The combination of niraparib and anlotinib did not show activity in patients with platinum-resistant OCCC. Clinical trial information: NCT05130515.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab plus platinum-based chemotherapy combined with anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer: A single-arm, open-label phase ? study (ALTN-AK105-II-06). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5528;
We will report more data in the future. Clinical trial information: ChiCTR2200062897.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5340;
P2
Anlotinib combined with sintilimab were preliminary shown promising efficacy with a favourable toxicity profile for patients with advanced nccRCC. Clinical trial information: NCT05220267.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5238;
P2
Anlotinib plus chemotherapy showed significant efficacy and manageable toxicities as first-line treatment in advanced gastrointestinal tumors with LMs, especially in pancreatic cancer, which might provide a new treatment strategy for those. Clinical trial information: NCT05262335.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Updated results from ALTER-H004 trial: Anlotinib combined with TACE as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgery () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5197;
P2
Anlotinib combined with TACE as adjuvant therapy in pts with HCC at high recurrent risk exhibited promising prognosis and tolerable safety profile preliminarily, and the conclusion needed to be confirmed in large-scale clinical trials subsequently. Clinical trial information: NCT04213118.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
The clinical efficacy and safety of sintilimab plus anlotinib for unresectable intrahepatic cholangiocarcinoma (ICC): A prospective, single-arm phase II study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5156;
Enrollment and further follow-up are ongoing. Clinical trial information: ChiCTR2000035901.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: A retrospective controlled study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5126;
Anlotinib combined with TACE may significantly improve outcomes for uHCC patients associated with hepatitis B virus comparing with TACE monotherapy with a controllable safety profile. Randomized controlled trials with a large sample are warranted to further validate the efficacy.
- Baizean (tislelizumab) / BeiGene, Novartis, Aqupla (nedaplatin) / Simcere, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib hydrochloride combined with tislelizumab, paclitaxel liposome, and nedaplatin regimen for preoperative neoadjuvant therapy of esophageal cancer: A single-arm, single-center, phase II exploratory clinical study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5076;
In order to provide a safe and reliable neoadjuvant therapy for patients with locally advanced esophageal cancer. Clinical trial information: ChiCTR2100049693.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase ? trial. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5038;
P2
TQB2450 plus anlotinib combined with paclitaxel and cisplatin showed significant efficacy and manageable safety profile as first-line treatment in advanced ESCC, which might provide a new treatment strategy for ESCC patients. Clinical trial information: NCT05013697.
- Opdivo (nivolumab) / Ono Pharma, BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5026;
P2
Anlotinib hydrochloride combined with Nivolumab showed effective clinical response and tolerable safety in second-line or later-line treatment of advanced gastric adenocarcinoma. Clinical trial information: NCT04503967.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4942;
P2
Serial ctDNA monitoring might become useful in an active surveillance strategy for the management of mCRC. Clinical trial information: NCT04080843.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Penpulimab combined with anlotinib therapy in patients with advanced refractory solid tumors: A single-center, observational, prospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4824;
Clinical trial information: NCT04080843. The combination of penpulimab plus anlotinib as a treatment for advanced refractory solid tumor showed the promising efficacy with a manageable safety profile, thereby suggesting that this combination therapy may be a viable treatment strategy for advanced refractory solid tumor patients.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4640;
P1
HFRT+IO+AAT is a promising therapeutic combination that may optimize abscopal responses, potentially even further than HFRT+LDRT+IO. This new
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib for patients with newly diagnosed glioblastoma with unmethylated MGMT promoter: An open-label, single-center, phase 2 clinical trial. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4541;
This new Given the temozolomide
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Mutational profiling of newly diagnosed glioblastoma to identify predictive biomarkers of efficacy and safety of anlotinib combination therapy. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4539;
P1/2
Given the temozolomide Our study suggested that alterations in HEG1, RP1L1 and PIK3CA could be novel biomarkers for the newly diagnosed GBM patients received anti-angiogenesis combination therapy, and provided now insights for the precise treatment of GBM.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4535;
The present study showed that anlotinib had a promising efficacy and favorable tolerability in treat rMG. Further randomized controlled clinical studies are needed to confirm the efficacy of Anlotinib for the treatment of rMG.
- Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
The efficacy and safety of anlotinib combined with bevacizumab in treatment of recurrent isocitrate dehydrogenase wildtype glioblastoma: A retrospective analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4532;
This is the first attempt to conduct dual antiangiogenic treatment in GBM patients. We demonstrate a promising result and suggest that this combination treatment may be a novel and safety treatment option for recurrent IDH-wt GBM patients.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4506;
We demonstrate a promising result and suggest that this combination treatment may be a novel and safety treatment option for recurrent IDH-wt GBM patients. The present study showed that anlotinib combined with TMZ had a promising efficacy in treating rHGG and TP53 was a potential biomarker to predict prognosis.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
A prospective, single-arm, single-center, exploratory clinical study of anlotinib combined with irinotecan in second-line and above treatment of HER-2 () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4331;
Further studies enrolling more patients are still needed. Clinical trial information: ChiCTR2000037448.
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS). (On Demand | Hall A; Poster Bd # 506) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2835;
Our data suggest that this combination has good tolerability and a prospective trial is warranted. Clinical trial information: ChiCTR2100053594.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated. (On Demand | Hall A; Poster Bd # 503) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2832;
Penpulimab(P) plus anlotinib(A) and epirubicin(E) has shown encouraging activity as firsy-line treatment for STS, which significantly prolong the PFS with well tolerance. Clinical trial information: ChiCTR2100048014.
- pimicotinib (ABSK021) / Abbisko, Conmana (icotinib) / Betta Pharma
Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update. (On Demand | Hall A; Poster Bd # 493) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2822;
P1
The changes in PD biomarkers indicate significant CSF-1R inhibition in TGCT pts. Updated data from 50 mg QD cohort showed higher ORR and continuous improvement over a longer treatment time, which supports the further evaluation of Pimicotinib in a phase 3 study.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial. (On Demand | Hall A; Poster Bd # 487) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2816;
This study suggested that anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance demonstrated encouraging efficacy with a manageable safety profile in the first line treatment of patients with advanced STS. Clinical trial information: ChiCTR2100054711.
- AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
Camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma: A single-arm, multicenter, exploratory study. (On Demand | Hall A; Poster Bd # 355b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2567;
P2
Secondary endpoints include disease control rate (DCR),progression-free survival (PFS), and 2-year overall survival (OS). Clinical trial information: NCT04979585.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study. (On Demand | Hall A; Poster Bd # 303) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2248;
Clinical trial information: NCT04979585. In conclusion, anlotinib holds promise in treating patients with advanced gynecological cancer, such as cervical, endometrial, and ovarian cancer, with reasonable efficacy and tolerable safety.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer. (On Demand | Hall A; Poster Bd # 293) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2238;
P2
Pathological CR was observed in patients with long-lasting PR, thus exploratory surgery may be required in selected patients. Clinical trial information: NCT04157491.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010). (On Demand | Hall A; Poster Bd # 270) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2215;
P2
Preliminary results of anlotinib combined with carboplatin/paclitaxel have shown favorable efficacy and tolerated safety profile in newly diagnosed advanced ovarian cancer patients. Clinical trial information: NCT04807166.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC). (On Demand | Hall A; Poster Bd # 98b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2112;
Currently, the study is active with 1 participant has been enrolled. Clinical trial information: ChiCTR2200063085.
- AL8326 / Advenchen
Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ?3rd line small cell lung cancer (SCLC) treatment. (On Demand | Hall A; Poster Bd # 212) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1971;
P1/2, P2
A US Phase 2 (NCT05363280) study is ongoing and a phase 3 study is in preparation. Clinical trial information: NCT04890795.
- Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC. (Live Stream | Hall D2; Poster Bd # 336) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1334;
P2
In pts with advanced BTC, sintilimab plus anlotinib plus GemCis significantly improved PFS and ORR vs GemCis with manageable safety, indicating sintilimab plus anlotinib plus GemCis may be a new first-line standard of care regimen. Clinical trial information: NCT04300959.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase ? clinical trial. (On Demand | Hall A; Poster Bd # 362) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1170;
P2
And the conclusions needed to be confirmed in trials continued subsequently. Clinical trial information: NCT05038813.
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P4 trial, Real-world evidence, Real-world, Metastases: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma (clinicaltrials.gov) - Apr 26, 2023
P4, N=360, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial: Anlotinib Capsules in the Treatment for IPF/PF-ILDs (clinicaltrials.gov) - Apr 25, 2023
P2/3, N=30, Recruiting, Sponsor: First Affiliated Hospital of Wenzhou Medical University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Enrollment change, Metastases: Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib (clinicaltrials.gov) - Apr 20, 2023
P2, N=20, Active, not recruiting, Sponsor: Yansong Lin
Clinical trial information: NCT05038813. Recruiting --> Active, not recruiting | N=10 --> 20
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Vizimpro (dacomitinib) / Pfizer
Enrollment open, Metastases: First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations (clinicaltrials.gov) - Apr 19, 2023
P1/2, N=140, Recruiting, Sponsor: Shanghai Chest Hospital
Recruiting --> Active, not recruiting | N=10 --> 20 Not yet recruiting --> Recruiting
- || AL2846 / Advenchen, Sino Biopharm
New P2 trial, Metastases: Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer (clinicaltrials.gov) - Apr 18, 2023
P2, N=40, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- || Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer (clinicaltrials.gov) - Apr 18, 2023
P2, N=48, Recruiting, Sponsor: Zhongnan Hospital
- | Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Combination therapy, Checkpoint inhibition, IO biomarker, Metastases: AK104IIT018: Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=44, Recruiting, Sponsor: Shanghai Chest Hospital
- | Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche
Trial completion date, Trial initiation date, Trial primary completion date: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Apr 13, 2023
P2, N=17, Recruiting, Sponsor: Binkui Li
Not yet recruiting --> Recruiting Trial completion date: May 2023 --> Dec 2023 | Initiation date: May 2022 --> May 2023 | Trial primary completion date: May 2023 --> Dec 2023
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P2 trial, Metastases: Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer (clinicaltrials.gov) - Apr 13, 2023
P2, N=20, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion date, Trial primary completion date, Metastases: Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma (clinicaltrials.gov) - Apr 12, 2023
P2, N=70, Recruiting, Sponsor: Sun Yat-sen University
Trial completion date: May 2023 --> Dec 2023 | Initiation date: May 2022 --> May 2023 | Trial primary completion date: May 2023 --> Dec 2023 Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Apr 12, 2023
P2, N=48, Active, not recruiting, Sponsor: Sun Yat-sen University
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> May 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: ALTER-HN005: Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 11, 2023
P2, N=110, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Clinical Trial,Phase II, Journal, Stroma, Metastases: Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study. (Pubmed Central) - Apr 10, 2023
Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> May 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study.
- || AiTan (rivoceranib) / HLB Bio Group
Trial completion, Metastases: A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Apr 7, 2023
P1, N=30, Completed, Sponsor: Elevar Therapeutics
Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study. Active, not recruiting --> Completed
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
PK/PD data, Journal: Population pharmacokinetics of anlotinib, a multiple receptor tyrosine kinase inhibitor, in chinese patients with malignant tumors. (Pubmed Central) - Apr 5, 2023
However, these differences were not clinically significant based on the simulations of the individual body weight effects. Taken together, this popPK model adequately described the pharmacokinetics of anlotinib in patients with malignant tumors and supports the same starting dose among them.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC (clinicaltrials.gov) - Apr 5, 2023
P=N/A, N=114, Not yet recruiting, Sponsor: Xijing Hospital
- | Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Metastases: Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance. (Pubmed Central) - Apr 4, 2023
Taken together, this popPK model adequately described the pharmacokinetics of anlotinib in patients with malignant tumors and supports the same starting dose among them. Osimertinib combined with anlotinib as three or more lines of treatment in advanced NSCLC was effective and adverse events were tolerable.
- | Journal: A Subset of VEGFR-TKIs Activates AMPK in LKB1-mutant Lung Cancer. (Pubmed Central) - Apr 4, 2023
This study discovered AMPK as an important off-target of apatinib, and elucidated different effects of this cluster of VEGFR-TKIs on AMPK. This finding can be the basis for the accurate and combined application of these drugs in clinic, and highlights the subset of VEGFR-TKIs including apatinib and anlotinib are potentially valuable in the treatment of LKB1-mutant NSCLC.